These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 19666448)

  • 1. Do bone morphogenic protein-4 antagonists have any role in the treatment of human hypertension?
    Yeter E; Kurt M; Ozçakar B; Denktaş AE
    Anadolu Kardiyol Derg; 2009 Aug; 9(4):356-7. PubMed ID: 19666448
    [No Abstract]   [Full Text] [Related]  

  • 2. Bone morphogenic protein antagonists are coexpressed with bone morphogenic protein 4 in endothelial cells exposed to unstable flow in vitro in mouse aortas and in human coronary arteries: role of bone morphogenic protein antagonists in inflammation and atherosclerosis.
    Chang K; Weiss D; Suo J; Vega JD; Giddens D; Taylor WR; Jo H
    Circulation; 2007 Sep; 116(11):1258-66. PubMed ID: 17785623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endothelium-derived bone morphogenic protein antagonists may counteract the proatherogenic vascular effects of bone morphogenic protein 4.
    Ungvari ZI
    Circulation; 2007 Sep; 116(11):1221-3. PubMed ID: 17846341
    [No Abstract]   [Full Text] [Related]  

  • 4. Targeting the arterial wall, but what is the target?
    Shantsila E; Lim HS
    J Hum Hypertens; 2009 Jan; 23(1):1-3. PubMed ID: 18509342
    [No Abstract]   [Full Text] [Related]  

  • 5. A rationale for treatment of endothelial dysfunction in hypertension.
    Ruschitzka F; Corti R; Noll G; Lüscher TF
    J Hypertens Suppl; 1999 Feb; 17(1):S25-35. PubMed ID: 10340841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of losartan, compared with atenolol, on endothelial function and oxidative stress in patients with type 2 diabetes and hypertension.
    Flammer AJ; Hermann F; Wiesli P; Schwegler B; Chenevard R; Hürlimann D; Sudano I; Gay S; Neidhart M; Riesen W; Ruschitzka F; Lüscher TF; Noll G; Lehmann R
    J Hypertens; 2007 Apr; 25(4):785-91. PubMed ID: 17351370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone morphogenic protein-4 induces hypertension in mice: role of noggin, vascular NADPH oxidases, and impaired vasorelaxation.
    Miriyala S; Gongora Nieto MC; Mingone C; Smith D; Dikalov S; Harrison DG; Jo H
    Circulation; 2006 Jun; 113(24):2818-25. PubMed ID: 16769910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Addressing those two that go together: the angiotensin II receptors and their role in blood-flow regulation.
    Fogari R; De Gasparo M
    Blood Press; 2001; 10(1):6-15. PubMed ID: 11332335
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of nebivolol on blood oxygen transport indices and endothelial dysfunction in patients with arterial hypertension.
    Pronko TP; Zinchuk VV
    Clin Physiol Funct Imaging; 2009 May; 29(3):170-6. PubMed ID: 19170724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Endothelial ion channels -- novel targets for antihypertensive therapy].
    Maier T; Grgic I; Busch C; Hoyer J; Köhler R
    Dtsch Med Wochenschr; 2005 Nov; 130(46):2637-9. PubMed ID: 16281159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of long-term antihypertensive therapy on vaso-regulating function of the brachial artery in patients with arterial hypertension associated with type 2 diabetes mellitus].
    Karpov RS; Koshel'skaia OA; Fal'kovskaia AIu; Ocheredko NA; Atroshenkov AV; Makarova EV
    Ter Arkh; 2003; 75(11):56-60. PubMed ID: 14708444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel therapeutic strategies targeting vascular endothelium in essential hypertension.
    Tousoulis D; Papageorgiou N; Androulakis E; Paroutoglou K; Stefanadis C
    Expert Opin Investig Drugs; 2010 Nov; 19(11):1395-412. PubMed ID: 20923260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance vessel structure: effects of treatment.
    Mulvany MJ
    J Cardiovasc Pharmacol; 1991; 17 Suppl 2():S58-63. PubMed ID: 1715487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Gestational arterial hypertension. Mechanisms of formation. Treatment with normodipin].
    Davidovich IM; Bloshchinskaia IA; Petrichko TA
    Ter Arkh; 2003; 75(10):50-4. PubMed ID: 14669607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High pressure induces superoxide production in isolated arteries via protein kinase C-dependent activation of NAD(P)H oxidase.
    Ungvari Z; Csiszar A; Huang A; Kaminski PM; Wolin MS; Koller A
    Circulation; 2003 Sep; 108(10):1253-8. PubMed ID: 12874194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of indapamide on muscle blood flow in hypertensive patients.
    Burgess CD; McKee CE; Wilson CA; Warren DJ
    Postgrad Med J; 1981; 57 Suppl 2():23-5. PubMed ID: 7322956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular effects of 15-F2t-isoprostane in spontaneously hypertensive rats.
    Marlière S; Cracowski JL; Hakim A; Stanke-Labesque F; Hoffmann P; Bessard G
    Can J Physiol Pharmacol; 2005 Jun; 83(6):453-8. PubMed ID: 16049544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Arterial stiffness: a tool to tailor antihypertensive therapy.
    Narain VS; Puri A
    Indian Heart J; 2008; 60(6):578-83. PubMed ID: 19276500
    [No Abstract]   [Full Text] [Related]  

  • 19. Adrenomedullin acts via stimulation of cyclic AMP and not via calcium signalling in vascular cells in culture.
    Barker S; Kapas S; Corder R; Clark AJ
    J Hum Hypertens; 1996 Jun; 10(6):421-3. PubMed ID: 8872811
    [No Abstract]   [Full Text] [Related]  

  • 20. [Calcium antagonists and endothelial function].
    Yasuda O; Kawamoto H; Yokoi T; Rakugi H; Ogihara T
    Clin Calcium; 2005 Oct; 15(10):1663-8. PubMed ID: 16199912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.